Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: USL261
DRUG: Placebo

Sponsor

UCB Biopharma S.P.R.L.